Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Other Working Capital Changes (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Other Working Capital Changes for 2 consecutive years, with -$495000.0 as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 98.52% to -$495000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.1 million through Dec 2025, down 413.46% year-over-year, with the annual reading at -$3.1 million for FY2025, 413.46% down from the prior year.
  • Other Working Capital Changes hit -$495000.0 in Q4 2025 for Xilio Therapeutics, up from -$40.7 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $38.9 million in Q2 2025 to a low of -$40.7 million in Q3 2025.